NewAmsterdam Pharma Corporation

NewAmsterdam Pharma is a late-stage biopharmaceutical company dedicated to improving patient care for populations with cardiometabolic and metabolic diseases. Its primary focus is advancing innovative, transformative therapies—such as CETP inhibitors like obicetrapib—for cardiovascular disease and other lipid-related conditions to address unmet medical needs where existing therapies are insufficient or poorly tolerated.